Tandem Diabetes Care (TNDM) Common Equity (2013 - 2026)

Tandem Diabetes Care's Common Equity history runs 14 years deep, the most recent figure standing at $132.4 million for Q1 2026.

• Quarterly Common Equity fell 14.74% year-over-year to $132.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $132.4 million (down 14.74% YoY) and the FY2025 annual result came in at $155.2 million, down 41.02% from the prior year.
• Common Equity was $132.4 million for Q1 2026 at Tandem Diabetes Care, down from $155.2 million in the prior quarter.
• Across five years, Common Equity topped out at $449.6 million in Q2 2022 and bottomed at $132.4 million in Q1 2026.
• A 5-year average of $278.3 million and a median of $263.1 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity soared 39.55% — and 2025, when it tumbled 44.06%.
• Tandem Diabetes Care's Common Equity stood at $439.9 million in 2022, then declined by 28.71% to $313.6 million in 2023, then dropped by 16.11% to $263.1 million in 2024, then plunged by 41.02% to $155.2 million in 2025, then decreased by 14.67% to $132.4 million in 2026.
• Business Quant data shows TNDM's Common Equity at $132.4 million in Q1 2026, $155.2 million in Q4 2025, and $133.0 million in Q3 2025.